Screener / SEC EDGAR /CIK 0001515673 /10-K filed Feb 18, 2026, compared with Feb 19, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Pharmaceuticals

Ultragenyx Pharmaceutical Inc. RARE

We are a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. 10-K, Item 1

Employees
1,371
Headquarters
Novato, CA
Next results
around Jan 11, 2027
Compare with peers Embed

RARE among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 20.2%, above 75% of 154 peers (their median 10.4%) REVENUE GROWTH 20.2% · above 75% Operating margin: -64.0%, above 9% of 138 peers (their median 10.2%) OPERATING MARGIN -64.0% · above 9% Net margin: -71.8%, above 8% of 153 peers (their median 6.8%) NET MARGIN -71.8% · above 8% FCF margin: -60.5%, above 8% of 144 peers (their median 10.1%) FCF MARGIN -60.5% · above 8%
RARE Peer median Below the median

What changed

16 new risk paragraphs. 10-K filed Feb 18, 2026 against Feb 19, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 11 checks found nothing to note

  • Receivables +29.5% ($122.0M to $158.0M) vs revenue +20.2% ($560.0M to $673.0M), +9.3 pts apart
  • Cash from operations −$466.0M vs net income −$575.0M (FY ending Dec 31, 2025)
  • Inventory +15.6% ($45.0M to $52.0M) vs revenue +20.2% ($560.0M to $673.0M), -4.6 pts apart
8 more checks with nothing to note
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Liabilities for sales of future royalties
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

16 paragraphs in Risk Factors that were not in the 10-K filed Feb 19, 2025. Quoted as filed.

All 16 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
    Our future financial performance depends on the successful commercialization of our products and product candidates.
  2. Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
    The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
    As we increase the number and range of our commercialized products, particularly as we prepare for launches of our first gene therapy products, we will need to expand our commercial and support teams to include additional expertise in those products. We may also experience additional complexities in our sales process and strategy and…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
    Regulatory standards are subject to change over time, making it difficult to accurately predict the likelihood of marketing approval even when clinical trials meet their endpoints. Regulatory standards are promulgated by various government entities and are subject to change based on factors such as scientific developments, public…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$363.3M$434.0M$560.0M$673.0M
Net income−$707.4M−$607.0M−$569.0M−$575.0M
Operating cash flow−$380.5M−$475.0M−$414.0M−$466.0M
Free cash flow−$496.6M−$519.0M−$421.0M−$472.0M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$673.0M ▲ 20.2% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

3 filings in the last 30 days · SEC EDGAR

All filings

About the company

Ultragenyx Pharmaceutical Inc., Novato, CA · from the 10-K filed Feb 18, 2026

We are a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. We have built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. We were founded in April 2010 by our President and Chief Executive Officer, Emil Kakkis, M.D., Ph. D., and are led by a management team experienced in the development and commercialization of rare disease therapeutics.

Headquarters
Novato, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 3, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, we had 1,371 total employees, of which 916 are in research and development and 455 are in sales, general, and administrative" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 18, 2026 (open at SEC), compared with the 10-K filed Feb 19, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RARE/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.